Implantica (OM:IMP A SDB) just crossed an important hurdle as its RefluxStop implant launched in the U.S. following FDA Premarket Approval, drawing strong interest at the American Foregut Society 2026 meeting.
Against that backdrop, Implantica’s share price has been volatile, with a 7 day share price return down 14.1% even though the year to date share price return is 24.95% and the 3 year total shareholder return sits at about 3.4x. This suggests longer term momentum while near term enthusiasm is taking a breather.
Scan beyond Implantica and compare it with 127 healthcare AI stocks that are also trying to turn new medical technology and digital treatment platforms into long-term investor returns.
Bulls point to FDA approval, rapid revenue expansion and a sizeable GERD market, while bears highlight ongoing losses and share price swings. Where does the current valuation place Implantica on that spectrum?
Most Popular Narrative: 28% Undervalued
Implantica last closed at SEK64.60, while the most followed narrative places fair value at about SEK90.05, which assumes a lot has to go right in the core RefluxStop rollout and beyond.
Impending U.S. approval of RefluxStop, supported by multiple favorable FDA inspections and clear remaining requirements, is expected to unlock a significantly larger addressable market and could drive a step change in revenue growth and operating leverage as U.S. volumes scale.
See why 1 investors see Implantica as 28% undervalued.
On those narrative assumptions, the fair value of SEK90.05 is being discounted back using a 5.66% rate, with analysts expecting very rapid revenue expansion and a shift toward double digit profit margins over time even though the business reported revenue of about €2.5m and a net loss of €19.7m in the most recent figures. The gap between the current price and that SEK90.05 figure reflects belief that high forecast top line growth of around 66.8% a year and eventual margin improvement will justify a rich future earnings multiple.
That story sits alongside some clear tension in the data. Implantica is still loss making, earnings are forecast to decline on average by 7.1% per year over the next 3 years, the 1 year total return is slightly negative at about 1.4% and the stock has been more volatile than the Swedish market despite a 3 year total shareholder return of roughly 2.4x. On top of that, the shares screen as expensive on a P/B basis at 21.1x versus 1.8x for the Swedish Medical Equipment industry, even though Simply Wall St’s DCF output points to a smaller discount of around 16% to an estimate of future cash flow value of SEK76.88.
It means this narrative hinges less on current profitability and more on the potential scale of the GERD opportunity, the FDA approved RefluxStop asset and management’s ability to convert clinical traction into meaningfully higher revenue over time while containing funding risk. Readers weighing that story may want to compare the SEK64.60 price, the SEK76.88 future cash flow estimate and the SEK90.05 narrative fair value, and then decide which set of assumptions best aligns with their own expectations for adoption, pricing and eventual earnings power.
Result: Fair Value of SEK90.05 (UNDERVALUED)
Still, slow U.S. reimbursement uptake or higher than expected commercialization costs could pressure Implantica’s cash position and undercut the high growth and margin assumptions behind that fair value story.
Find out about the key risks to this Implantica narrative.
Next Steps
If this mix of optimism and caution around Implantica feels familiar, consider taking action while the details are fresh and weigh the trade off yourself with 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Implantica?
Do not stop your research with Implantica. Broaden your watchlist now using targeted stock ideas that match different investing goals and risk levels.
- Explore higher upside potential by reviewing carefully selected small companies through the 125 elite penny stocks with strong financials.
- Focus on quality at a reasonable price by scanning for companies that look attractively priced on fundamentals with the 173 high quality undervalued stocks.
- Emphasise resilience and capital protection by focusing on companies with steadier profiles using the 223 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com